Skip to main content
Journal of Market Access & Health Policy logoLink to Journal of Market Access & Health Policy
. 2020 Mar 9;8(1):1738637. doi: 10.1080/20016689.2020.1738637

Specialist physician perspectives on non-medical switching of prescription medications

Olivia S Costa a,b, Tabassum Salam c, Amy Duhig d, Aarti A Patel e, Ann Cameron d, Jennifer Voelker e, Brahim Bookhart e, Craig I Coleman a,b,
PMCID: PMC7144249  PMID: 32284826

ABSTRACT

Introduction: A non-medical switch is a change to a patient’s medication regimen for reasons other than lack of clinical response, side-effects or poor adherence. Specialist physicians treat complex patients who may be vulnerable to non-medical switching.

Objectives: To evaluate specialist physicians’ perceptions regarding the frequency of non-medical switch requests, and the impact on their patients’ outcomes and healthcare utilization.

Methods: An online survey of randomly sampled physicians spending ≥10% of time providing patient care and having received ≥1 non-medical switch request during the prior 12-months.

Results: Among 404 specialist physicians surveyed, non-medical switch requests were reported as very frequent or frequent by 35.0% of oncologists (for injectable cancer agents) and up to 80.3% of endocrinologists (for injectable anti-hyperglycemics). Respondents reported decreased medication effectiveness (25.0% of oncologists to 75.0% of dermatologists) and increased side-effects (32.5% of oncologists to 66.7% of psychiatrists). Most specialists reported very frequent or frequent increases in non-office visits (52.5% of oncologists to 75.3% of endocrinologists) and calls with pharmacies (57.5% of oncologists to 80.5% of rheumatologists) due to non-medical switching.

Conclusions: Receipt of non-medical switching requests were common among specialist physicians. Non-medical switching may lead to negative effects on patient care and require increased healthcare utilization.

KEYWORDS: Non-medical switch, outcome assessment, specialization, therapeutic interchange

Introduction

Non-medical switching is defined as a change in a stable patient’s prescribed medication to a clinically distinct, non-generic alternative for reasons other than poor clinical response, side-effects or non-adherence [14]. Non-medical switching is often the result of medication cost containment strategies implemented by insurers (e.g., formulary changes, prior authorization, step therapy) [2,3].

Specialist physicians may be particularly weary of non-medical switching because they more frequently care for ‘complex’ patients compared to primary care physicians (albeit varying degrees of complexity across various medical specialties)[5]. Although there is no widely accepted definition of a complex patient, prior evaluations have incorporated the number of prescriptions, comorbid conditions, socioeconomic circumstances and healthcare utilization [57]. Often patients managed by specialists are referred by primary care physicians after their initial treatment plans were not fully successful, necessitating the use of newer, more costly therapies or off-label medications to achieve desired goals [8,9]. Treatment plans designed by specialists may take months before a condition is successfully controlled[10]. The commonplace requirement for non-medical switching may threaten patient’s ability to persist on their regimen[11].

We performed a cross-sectional survey study to explore specialty physicians’ perceptions regarding the impact of non-medical switching on their prescription of certain medication classes, patient outcomes and healthcare utilization.

Methods

We conducted an on-line cross-sectional survey of physicians[12]. Physicians were identified and recruited by Research Now-Survey Sampling International using their voluntary physician panel derived from state licensing and professional association data. Physicians were randomly sampled, sent an email invitation to opt-in to participate in the survey and were provided a modest honorarium upon survey completion.

The study intended to enroll ~400 specialty physicians, with quotas for individual subspecialties set a priori (cardiology, n = 80; dermatology, n = 40; endocrinology, n = 80; gastroenterology, n = 40; oncology, n = 40; psychiatry, n = 80; and rheumatology, n = 40). Prior to being allowed to participate in the full survey, physicians first had to complete a screener in order to determine whether they met the present study’s inclusion criteria including being a licensed specialist (cardiologist, dermatologist, endocrinologist, gastroenterologist, oncologist, psychiatrist or rheumatologist) physician currently practicing (post-residency and/or fellowship >2 years but <30 years); spending a minimum of 10% of their professional time providing direct patient care and had received a request for a non-medical switch for at least one patient in prior 12-months. All eligible participants based on the screener questions were invited to complete the online survey. The survey was administered using the Decipher online survey platform (FocusVision, New York, NY, USA) and was fielded in November through December 2018. Investigators were blinded to all respondents to remain compliant with the Health Insurance Portability and Accountability Act. The study was approved by an independent institutional review board (Solutions IRB, Yarnell, AZ, USA) and reporting of results follow American Association for Public Opinion Research guidance[13].

The present study examines the impact of non-medical switching on physicians’ use, stratified by specialty type, of certain medication classes, patient outcomes and healthcare utilization. Survey questions were framed as either 5-point (‘Very Frequently’, ‘Frequently’, ‘Occasionally’, ‘Rarely’, ‘Never’) or 7-point (‘Increases Greatly’, ‘Increases Very Much’, ‘Increases Somewhat’, ‘No Change’, ‘Decreases Somewhat’, ‘Decreases Very Much’, or ‘Decreases Greatly’) ordinal Likert scales. Data regarding physician’s demographics and professional/practice characteristics were also collected and reported. Responses to the question regarding the frequency in which non-medical switching impacted physicians’ prescribing of medication classes was only reported for a specialty type if ‘not applicable’ was selected <5% of the time. The analysis of our survey data was descriptive in nature. Categorical variables were summarized as counts and percentages and continuous measures as means with standard deviations (SDs) or medians with ranges. Statistical analysis was conducted using IBM SPSS version 26.0 (IBM Corp., Armonk, NY, USA).

Results

In total 21,493 physicians from the RN-SSI panel were available for recruitment into this survey study. Email invitations to opt-in (consent) were sent to a random sample of 13,117 physicians of which 1,818 opened the email and clicked on the embedded survey link. The main study included responses from 1,010 physicians who passed the screener, met all study inclusion criteria and completed the survey. Of these, 404 were specialist physicians and were included in the present analysis.

Demographic and physician practice characteristics are summarized in Table 1. Specialties included cardiology, dermatology, endocrinology, gastroenterology, oncology, psychiatry and rheumatology. Majority of responding physicians were men (ranging from 54.3% for endocrinologists to 85.0% for gastroenterologists). Between 60.0% (dermatology) and 85.2% (cardiology) of physicians reported being in practice for ≥10-years. Private practice was most common among dermatologists (82.5%), endocrinologists (65.4%), gastroenterologists (57.5%) and rheumatologists (51.2%). The most common settings for cardiologists were community hospital and private practice (45.7% and 44.4%, respectively); oncologists were academic hospital and private practice (47.5% and 35.0%, respectively); and psychiatrists were private practice and outpatient centers (44.4% and 37.0%, respectively). More than 97% of all specialist reported spending over half of their time providing direct patient care.

Table 1.

Demographic and physician site characteristics

     
Specialty
CardiologyN = 81 DermatologyN = 40 Endocrinology
N = 81
GastroenterologyN = 40 OncologyN = 40 PsychiatryN = 81 RheumatologyN = 41
Age (mean±SD)   52.3 ± 9.15 47.4 ± 9.09 48.1 ± 9.39 52.5 ± 8.74 47.2 ± 8.58 49.9 ± 9.49 49.2 ± 10.36
Sex Female 17.3% 42.5% 43.2% 12.5% 22.5% 40.7% 39.0%
Male 80.2% 55.0% 54.3% 85.0% 75.0% 55.6% 61.0%
Not reported 2.5% 2.5% 2.5% 2.5% 2.5% 3.7% 0.0%
Practice Setting Academic/teaching hospital 35.8% 5.0% 27.2% 20.0% 47.5% 17.3% 39.0%
Outpatient centers (hospital affiliated) 18.5% 15.0% 21.0% 20.0% 20.0% 37.0% 17.1%
Community hospital 45.7% 2.5% 13.6% 37.5% 22.5% 16.0% 12.2%
Private practice 44.4% 82.5% 65.4% 57.5% 35.0% 44.4% 51.2%
Ambulatory surgical center 3.7% 0.0% 0.0% 20.0% 0.0% 0.0% 0.0%
Other 0.0% 0.0% 0.0% 0.0% 0.0% 11.1% 0.0%
Characteristics of Private Practice Solo practice 30.6% 18.2% 9.4% 26.1% 14.3% 50.0% 42.9%
Partnership (2 physicians) 8.3% 21.2% 17.0% 4.3% 14.3% 2.8% 9.5%
Same-specialty group practice (≥3 physicians) 44.4% 42.4% 24.5% 47.8% 57.1% 38.9% 33.3%
Multi-specialty group practice (≥3physicians) 16.7% 18.2% 49.1% 21.7% 14.3% 8.3% 14.3%
Proportion of Time Covered by                
Medicaid <25% 85.3% 90.0% 75.6% 67.5% 73.5% 48.6% 75.0%
25 to 49% 12.0% 7.5% 15.4% 32.5% 23.5% 28.4% 19.4%
50 to 74% 2.7% 2.5% 9.0% 0.0% 2.9% 10.8% 5.6%
≥75% 0.0% 0.0% 0.0% 0.0% 0.0% 12.2% 0.0%
Medicare/Medicare Advantage <25% 10.7% 37.5% 28.2% 37.5% 23.5% 68.9% 22.2%
25 to 49% 36.0% 52.5% 59.0% 55.0% 52.9% 24.3% 72.2%
50 to 74% 41.3% 10.0% 11.5% 7.5% 23.5% 6.8% 5.6%
≥75% 12.0% 0.0% 1.3% 0.0% 0.0% 0.0% 0.0%
Commercial <25% 18.7% 2.5% 9.0% 0.0% 11.8% 20.3% 8.3%
25 to 49% 56.0% 20.0% 33.3% 42.5% 38.2% 33.8% 41.7%
50 to 74% 22.7% 55.0% 44.9% 47.5% 47.1% 24.3% 44.4%
≥75% 2.7% 22.5% 12.8% 10.0% 2.9% 21.6% 5.6%
Uninsured/unable to pay <25% 96.0% 100.0% 100.0% 100.0% 100.0% 91.9% 97.2%
25 to 49% 4.0% 0.0% 0.0% 0.0% 0.0% 5.4% 2.8%
50 to 74% 0.0% 0.0% 0.0% 0.0% 0.0% 2.7% 0.0%
≥75% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Not reported   8.0% 0.0% 3.8% 0.0% 17.6% 9.5% 13.9%
Reimbursement Mechanisms Fee for service 42.0% 65.0% 43.2% 50.0% 40.0% 42.0% 31.7%
Value-based payment arrangements 23.5% 32.5% 29.6% 20.0% 20.0% 8.6% 43.9%
Salary 58.0% 25.0% 55.6% 50.0% 57.5% 63.0% 51.2%
Other 0.0% 0.0% 0.0% 2.5% 0.0% 2.5% 0.0%
Census Region Northeast 23.5% 25.0% 34.6% 17.5% 32.5% 23.5% 34.1%
Midwest 23.5% 20.0% 23.5% 20.0% 32.5% 23.5% 17.1%
South 33.3% 45.0% 28.4% 27.5% 15.0% 35.8% 34.1%
West 19.8% 10.0% 13.6% 35.0% 20.0% 17.3% 14.6%
Years of Practice < 10 years 14.8% 40.0% 28.4% 15.0% 22.5% 22.2% 31.7%
10 to 19 years 39.5% 27.5% 38.3% 25.0% 47.5% 40.7% 39.0%
≥20 years 45.7% 32.5% 33.3% 60.0% 30.0% 37.0% 29.3%
Proportion of Time Providing Direct Patient Care 10 to 24% 0.0% 0.0% 0.0% 0.0% 2.5% 0.0% 0.0%
25 to 49% 0.0% 0.0% 1.2% 0.0% 0.0% 0.0% 0.0%
50 to 74% 1.2% 2.5% 2.5% 2.5% 7.5% 6.2% 0.0%
≥75% 98.8% 97.5% 96.3% 97.5% 90.0% 93.8% 100.0%

Specialist familiarity with the term non-medical switching is reported in Table 2. The majority (>55%) of responding cardiologists, dermatologists, endocrinologists and psychiatrists) were not familiar with the term” non-medical switching” prior to survey participation. Gastroenterologist, oncologists, and rheumatologist were more familiar, with 52.5%, 60.0% and 56.2%, respectively reported they heard the term prior to survey participation.

Table 2.

Familiarity with the term ‘Non-Medical Switching’

    Specialty
CardiologyN = 81 DermatologyN = 40 EndocrinologyN = 81 GastroenterologyN = 40 OncologyN = 40 PsychiatryN = 81 RheumatologyN = 41
Physicians have heard the term ‘non-medical switching’ prior to survey participation Yes 24 29.6% 16 40.0% 25 30.9% 21 52.5% 24 60.0% 26 32.1% 23 56.1%
No 48 59.3% 22 55.0% 48 59.3% 13 32.5% 13 32.5% 47 58.0% 14 34.1%
Unsure 9 11.1% 2 5.0% 8 9.9% 6 15.0% 3 7.5% 8 9.9% 4 9.8%

Table 3 summarizes how often specialists were asked to comply with a non-medical switch for each of the medication classes. Most specialists reported at least occasional requests for non-medical switches. Endocrinologists had the highest rates of non-medical switch requests with 80.3%, 70.4% and 48.2% reporting frequent or very frequent requests for injectable anti-hyperglycemics, oral anti-hyperglycemics and hormone replacement therapy, respectively. Conversely, oncologists had the lowest rates of non-medical switch requests with only 35.0% and 37.5% reporting frequent or very frequent requests to injectable and oral cancer agents, respectively. Requests for a non-medical switch was reported as frequent or very frequent by 52.5% of gastroenterologists (for immunomodulatory agents) and 60.5% of psychiatrists (for psychoactive medications). For antihypertensives, lipid-lowering agents and anticoagulants/antiplatelets there were 42.0%, 43.2% and 50.6% of cardiologists that reported frequent or very frequent non-medical switch requests. For immunomodulatory agents and pain medications there were 61.0% and 51.2% of rheumatologists, respectively that reported frequent or very frequent non-medical switch requests.

Table 3.

Frequency of mon-medical switching for various medication classes

graphic file with name ZJMA_A_1738637_ILG0001.gif

The perceived impact of non-medical switching on patient outcomes is reported in Table 4. Respondents often felt their patients experienced a negative impact on the effectiveness of a medication following a non-medical switch (ranging from 25.0% of oncologists, up to 75.0% for dermatologists). Side-effects were reported to increase by many respondents (ranging from 32.5% of oncologists, up to 66.7% of psychiatrists). Medication adherence was also found to be negatively impacted (30.0% for oncologists, up to 67.5% for dermatologists). The out of pocket costs for medication was commonly reported to increase (ranging from 40.7% for endocrinologists, up to 58.0% for psychiatrists). Nearly half of respondents reported increased abandonment of treatment (ranging from 45.0% for oncologists and gastroenterologists, up to 67.5% for dermatologists). Respondents reported an increased frequency of medication errors (ranging from 42.0% for psychiatrists, up to 60.5% for endocrinologists). Patient’s confidence and trust in their physician were commonly reported as neutral in all specialties except by dermatology in which 47.5% reported decreased trust in their physician’s ability to effectively practice medicine.

Table 4.

Perceived effects of non-medical switching by participants

graphic file with name ZJMA_A_1738637_ILG0002.gif

The majority of specialist physicians reported frequent or very frequent increases in non-office visit contacts (i.e. phone calls and emails) (ranging from 52.5% for oncologists, up to 75.3% for dermatologists) and increased calls with pharmacies (57.5% for oncologists, up to 80.5% for rheumatologists) (Table 5). About a third of specialists reported frequent or very frequent increases in office visits (22.2% for endocrinologists, up to 41.5% for rheumatologists). The need for laboratory testing and/or additional medications varied among specialties. Frequent or very frequent increase of laboratory testing were reported by 13.6% of psychiatrists to 43.9% of rheumatologists and frequent or very frequent increase of additional medications were reported by 14.8% of endocrinologists to 42.5% of dermatologists. Emergency department visits and hospitalizations were less frequently impacted by non-medical switching, though emergency department visits (3.7% of dermatologists to 30.0% of oncologists) and hospitalizations (8.6% of endocrinologists to 17.5% of oncologists) were still reported to very frequently or frequently increase.

Table 5.

Utilization of the health care system following non-medical switching

graphic file with name ZJMA_A_1738637_ILG0003.gif

Discussion

This present, online, cross-sectional survey study of specialist physicians found that ≤60% were previously familiar with the term non-medical switch prior to the survey, however all had experience with it in their clinical practice. Over one-third of physicians in every specialty reported frequent or very frequent non-medical switch requests in their applicable medication classes with over half reporting at least an occasional non-medical switch request. Furthermore, majority of specialists reported negative or neutral patient outcomes in terms of treatment effectiveness, side-effects, adherence, out-of-pocket medication costs, abandonment of treatment, medication errors, patient confidence and trust in their physician. Lastly, specialists reported occasional to frequent increases in healthcare utilization through office visits, non-office visit contact, laboratory testing and communication with pharmacies, and less often (but still occurring) with emergency department visits and hospitalizations.

Our study focused on specialist physicians because they are responsible for managing medications for the most complex of patients; a population in whom a successful treatment regimen is often challenging to develop[5]. A study by Tonelli and colleagues of primary care physicians (i.e., family physicians, general internist) and 11 sub-specialties evaluated patient ‘complexity’ in terms of number of comorbidities, risk of mental health conditions, number of prescribed medications, number of physician types, number of physicians, length of stay in hospital, emergency department visits, long-term care placement and risk of mortality. The study found that many specialist physicians including nephrologists, infectious disease specialists, neurologists, respirologists, hematologists, rheumatologists, gastroenterologists and cardiologist were more likely to treat more complex patients as compared to primary care providers[5]. Of the specialties evaluated in Tonelli et al. and our survey study; rheumatologists, cardiologists and gastroenterologists were found to have higher complexity in terms of prescribed medications compared to primary care physicians[5]. Specialists may encourage or utilize newer medications more frequently than primary care physicians [8] due to this increased complexity of patients they treat, and these medications are often more costly due to a lack of generic availability.

Specialist physicians’ perceptions of the impact of non-medical switching on clinical and healthcare utilization outcomes observed in our study are generally consistent with those from a recently published systematic review on the topic[11]. This systematic review by Weeda and colleagues evaluated the impact of non-medical switching on four domains (clinical, economic, resource utilization and medication taking behaviors). The review included 38 real-word studies that evaluated non-medical switching in the US. Overall, the outcomes were reported as neutral or negative in over 90% of cases. Specifically, the authors found outcomes relating to clinical, economic, health-care utilization and medication taking behaviors were negative or neutral in 86.0%, 95.9%, 97.0%, and 100% of cases respectively.

Our study has limitations worth noting. First, as with any self-reported response survey, social desirability bias (whereby respondents answer questions in a manner they feel will be viewed positively by others) may exist[14]. Next, our study had a small sample size of specialists from limited areas; notably we did not have respondents from the specialties of infectious disease, nephrology, neurology or respiratory which may have resulted in decreased applicability to various medication classes (e.g., epileptic medications, inhalers, antiretrovirals, etc). Finally, to avoid respondent burden[12], we restricted the number of questions asked and did not offer respondents the opportunity to provide an explanation or more nuanced response.

In summary, this cross-sectional survey study suggests non-medical switching occurs frequently across a range of specialties in various medication classes. Furthermore, non-medical switching may lead to negative effects on patient care and require increased utilization of the healthcare system. Medical societies and patient advocacy groups should provide as much guidance as possible regarding when and how (if at all) non-medical switching should be performed.

Funding Statement

This work was financially supported by Janssen Scientific Affairs, LLC, to Xcenda, a health economics consultancy providing services to the life science industry.

Disclosure statement

T.S. has disclosed that she is employed by the American College of Physicians and was a consultant to Janssen on this study.

A.D. and A.C. have disclosed that they are employees of Xcenda which received funding for this study from Janssen

A.P., J.V, and B.B have disclosed that they are employees and shareholders of Janssen.

C.I.C reported grants and consulting fees from the Janssen Scientific Affairs LLC, Bayer AG, Portola Pharmaceuticals.

O.S.C. has no conflicts of interest to declare.

References

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Citations

  1. American Medical Association . H-125.991 Drug formularies and therapeutic interchange. Available at: https://policysearch.ama-assn.org/policyfinder/detail/Drug%20Formularies%20and%20Therapeutic%20Interchange%20H-125.991?uri=%2FAMADoc%2FHOD.xml-0-227.xml. [cited 2019 November4
  2. Prior Authorization and Utilization Management Reform Principles . American Medical Association. 2017. [cited 2019 November4]. Available from: https://www.ama-assn.org/sites/default/files/media-browser/principles-with-signatory-page-for-slsc.pdf

Articles from Journal of Market Access & Health Policy are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES